Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Salsola oppositifolia allergenic extract: in vivo determination of allergenic potency in histamine equivalent prick units
2006-003408-20Phase 2Completed
- Sponsor
- LETI Pharma
- Start
- Mar 2007
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of salsola oppositifolia allergenic extract in allergic rhinitis (AR), allergic asthma and pollinosis, sponsored by LETI Pharma. Primary endpoint: Wheal size after prick testing. Started Mar 2007; status: completed.
02
Drugs
salsola oppositifolia allergenic extract
03
Conditions
allergic rhinitis (AR)allergic asthmapollinosis
Beyond the preview
Go deeper on 2006-003408-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003408-20.